| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FUCA2 |
| Uniprot No | Q9BTY2 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 29-467aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMGSHSATRFDPTWESLDARQLPAWFDQAKF GIFIHWGVFSVPSFGSEWFWWYWQKEKIPKYVEFMKDNYPPSFKYEDFGP LFTAKFFNANQWADIFQASGAKYIVLTSKHHEGFTLWGSEYSWNWNAIDE GPKRDIVKELEVAIRNRTDLRFGLYYSLFEWFHPLFLEDESSSFHKRQFP VSKTLPELYELVNNYQPEVLWSDGDGGAPDQYWNSTGFLAWLYNESPVRG TVVTNDRWGAGSICKHGGFYTCSDRYNPGHLLPHKWENCMTIDKLSWGYR REAGISDYLTIEELVKQLVETVSCGGNLLMNIGPTLDGTISVVFEERLRQ MGSWLKVNGEAIYETHTWRSQNDTVTPDVWYTSKPKEKLVYAIFLKWPTS GQLFLGHPKAILGATEVKLLGHGQPLNWISLEQNGIMVELPQLTIHQMPC KWGWALALTNVI |
| 预测分子量 | 53 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于FUCA2重组蛋白的模拟参考文献(内容基于领域常见研究主题，非真实文献)：
1. **《FUCA2 functions as a tumor suppressor in hepatocellular carcinoma by modulating EGFR signaling》**
- 作者：Zhang, Y. et al.
- 摘要：研究通过重组FUCA2蛋白体外实验，证实其通过降解EGFR岩藻糖基化修饰抑制肝癌细胞增殖和迁移，为FUCA2的抑癌机制提供分子证据。
2. **《Recombinant human α-L-fucosidase 2 (FUCA2): enzymatic characterization and role in lysosomal storage disorders》**
- 作者：Smith, J.R. & Brown, K.L.
- 摘要：报道重组FUCA2蛋白在HEK293细胞中的高效表达与纯化，分析其酶动力学参数及底物特异性，探讨其在岩藻糖苷贮积症治疗中的潜在应用。
3. **《Structural insights into the catalytic mechanism of recombinant FUCA2 using X-ray crystallography》**
- 作者：Johnson, M.T. et al.
- 摘要：解析重组FUCA2蛋白的晶体结构，揭示其活性位点关键氨基酸残基及岩藻糖水解机制，为设计靶向抑制剂提供结构基础。
4. **《Serum FUCA2 as a biomarker for inflammatory bowel disease: Development of a recombinant protein-based ELISA assay》**
- 作者：Wang, H. et al.
- 摘要：利用重组FUCA2蛋白建立ELISA检测方法，发现其在炎症性肠病患者血清中水平显著降低，提示其作为疾病诊断标志物的潜力。
**注**：以上文献名为示例性模拟，实际文献需通过PubMed/Google Scholar等平台以“FUCA2 recombinant protein”为关键词检索获取。
Fucosidase alpha-L-2 (FUCA2) is a lysosomal enzyme encoded by the *FUCA2* gene in humans. It belongs to the glycosyl hydrolase family and catalyzes the hydrolysis of α-1.6-linked fucose residues from glycoproteins, glycolipids, and oligosaccharides. This post-translational modification is critical for cellular processes such as protein trafficking, immune response modulation, and pathogen recognition. Unlike its homolog FUCA1. which is ubiquitously expressed, FUCA2 shows tissue-specific expression, predominantly in the epididymis, kidneys, and brain, suggesting specialized roles in reproductive and neurological functions.
Recombinant FUCA2 protein is engineered through genetic cloning techniques, typically using prokaryotic (e.g., *E. coli*) or eukaryotic (e.g., mammalian, insect cell) expression systems. The recombinant form retains the enzymatic activity of native FUCA2. enabling its use in functional studies, diagnostic assays, and therapeutic development. Its production often involves affinity tag purification (e.g., His-tag) to ensure high yield and purity.
Research on FUCA2 has gained momentum due to its association with diseases. While mutations in *FUCA1* cause the rare lysosomal storage disorder fucosidosis, FUCA2 is implicated in metabolic dysregulation, cancer progression, and neurodegenerative conditions. For example, altered FUCA2 activity has been observed in glioblastoma and prostate cancer, where fucose metabolism influences tumor invasiveness. Recombinant FUCA2 serves as a tool to investigate these mechanisms and explore enzyme replacement therapies. Additionally, it aids in developing biomarkers for early disease detection and monitoring therapeutic efficacy in preclinical models.
×
